title: Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease.
abstract: Chronic venous disease (CVeD) is a debilitating condition that affects millions of individuals worldwide. The condition can result in varicose veins, or advance to severe skin changes and venous ulceration. The fundamental basis for CVeD is inflammation within the venous circulation and that it is subjected to increased hydrostatic pressure resulting in increased ambulatory venous pressure. The inflammation involves leukocytes, in particular macrophages and monocytes, inflammatory modulators and chemokines, cytokine expression, growth factors, metalloproteinase (MMP) activity, and many regulatory pathways that perpetuate inflammation. Sulodexide (SDX) is a glycosaminoglycan with pro-fibrinolytic and anti-thrombotic properties. We have previously demonstrated that SDX inhibits the secretion of pro-zymogen MMP-9 from human leukocytes without displacing high molecular complexes of MMP-9. The anti-inflammatory properties of SDX on activated leukocytes have not been well established. We hypothesized that SDX will reduce the secretion of inflammatory mediators from lipopolysaccharide (LPS)-stimulated macrophages. Therefore, we evaluated the effects of SDX on LPS-stimulated macrophage secretion of various inflammatory and anti-inflammatory cytokines, chemokines, and colony stimulating factors. We used microplatebased multiplex immunoassays. LPS-stimulated macrophages in vitro caused a substantial increase of interleukins, tumor necrosis factor, interferon, chemokines and colony stimulating factors. The addition of SDX caused both a dose-dependent and dose-independent decrease in nearly all of the inflammatory cytokines, chemokines and colony stimulating factors. These findings suggest that SDX has a significant effect on the release of inflammatory mediators from macrophages, and may be useful in the treatment of early and advanced CVeD.
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Mannello
authors.forename: Daniela
authors.initials: D
authors.lastname: Ligi
authors.forename: Matteo
authors.initials: M
authors.lastname: Canale
authors.affiliation: Department of Biomolecular Sciences, Section of Clinical Biochemistry and Cell Biology, University "Carlo Bo", Via O. Ubaldini 7, Urbino (PU), Italy. ferdinando.mannello@uniurb.it.
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Raffetto
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D018925:Chemokines / Q000276:immunology / Q000378:metabolism; D002908:Chronic Disease; D003115:Colony-Stimulating Factors / Q000276:immunology / Q000378:metabolism*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000494:pharmacology*; D016179:Granulocyte Colony-Stimulating Factor / Q000276:immunology / Q000378:metabolism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology; D020298:U937 Cells; D014648:Varicose Veins / Q000276:immunology / Q000517:prevention & control*
chemical_list: D000893:Anti-Inflammatory Agents; D018925:Chemokines; D003115:Colony-Stimulating Factors; D016207:Cytokines; D006025:Glycosaminoglycans; D008070:Lipopolysaccharides; D016179:Granulocyte Colony-Stimulating Factor; C007858:glucuronyl glucosamine glycan sulfate; D016178:Granulocyte-Macrophage Colony-Stimulating Factor